From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox.
anemia
deferasirox
iron chelation therapy (ICT)
iron toxicity
myelodysplastic syndromes (MDS)
myelofibrosis (MF)
radical oxygen species (ROS)
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
02
08
2021
accepted:
08
09
2021
entrez:
25
10
2021
pubmed:
26
10
2021
medline:
26
10
2021
Statut:
epublish
Résumé
Iron chelation therapy (ICT) has become a mainstay in heavily transfused hematological patients, with the aim to reduce iron overload (IOL) and prevent organ damage. This therapeutic approach is already widely used in thalassemic patients and in low-risk Myelodysplastic Syndrome (MDS) patients. More recently, ICT has been proposed for high-risk MDS, especially when an allogeneic bone marrow transplantation has been planned. Furthermore, other hematological and hereditary disorders, characterized by considerable transfusion support to manage anemia, could benefit from this therapy. Meanwhile, data accumulated on how iron toxicity could exacerbate anemia and other clinical comorbidities due to oxidative stress radical oxygen species (ROS) mediated by free iron species. Taking all into consideration, together with the availability of approved oral iron chelators, we envision a larger use of ICT in the near future. The aim of this review is to better identify those non-thalassemic patients who can benefit from ICT and give practical tips for management of this therapeutic strategy.
Identifiants
pubmed: 34692534
doi: 10.3389/fonc.2021.752192
pmc: PMC8527180
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
752192Informations de copyright
Copyright © 2021 Palumbo, Galimberti, Barcellini, Cilloni, Di Renzo, Elli, Finelli, Maurillo, Ricco, Musto, Russo and Latagliata.
Déclaration de conflit d'intérêts
GP has received honoraria and/or served on the scientific advisory boards for Abbvie, Amgen, AOP, AstraZeneca, BMS Celgene, Janssen, and Novartis. WB: Consultant Novartis. EE: Participation to advisory board Novartis. CF: Novartis: advisory committees, speaker fees; Celgene: research funding, advisory committees, speaker fees; Takeda: consultancy. PM has received honoraria and/or served on the scientific advisory boards for Celgene, Janssen, Takeda, Bristol-Myers Squibb, Amgen, Novartis, Gilead, Jazz, Sanofi, Abbvie, Incyte, and Glaxo-Smith-Kline. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Leukemia. 2017 Sep;31(9):1962-1974
pubmed: 28008177
Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
Hemasphere. 2020 May 27;4(3):e357
pubmed: 32647792
Eur J Haematol. 2011 Oct;87(4):338-48
pubmed: 21649735
Br J Haematol. 2011 Apr;153(1):111-7
pubmed: 21332704
Acta Haematol. 2009;122(2-3):165-73
pubmed: 19907154
Adv Exp Med Biol. 2015;866:83-9
pubmed: 26022903
Br J Haematol. 2020 Jun;189(5):888-903
pubmed: 32017044
Blood. 2013 Oct 24;122(17):2943-64
pubmed: 23980065
Blood Rev. 2016 Sep;30(5):349-56
pubmed: 27106071
J Natl Compr Canc Netw. 2017 Jan;15(1):60-87
pubmed: 28040720
Mayo Clin Proc. 2012 Jan;87(1):25-33
pubmed: 22212965
Int J Hematol. 2018 Jan;107(1):55-63
pubmed: 29177643
Am J Kidney Dis. 2003 Dec;42(6):1164-8
pubmed: 14655187
PLoS One. 2011;6(8):e23109
pubmed: 21886780
Am J Hematol. 2017 May;92(5):420-428
pubmed: 28142202
Br J Haematol. 2019 Sep;186(5):e123-e126
pubmed: 31106402
Clin Exp Med. 2020 Feb;20(1):1-9
pubmed: 31712933
Blood Rev. 2011 Jan;25(1):17-31
pubmed: 21030120
Ann Intern Med. 2020 Apr 21;172(8):513-522
pubmed: 32203980
Front Pharmacol. 2014 May 05;5:94
pubmed: 24847266
Blood. 2013 Dec 12;122(25):4047-53
pubmed: 24174625
Crit Rev Oncol Hematol. 2017 Sep;117:57-66
pubmed: 28807236
Leuk Res. 2014 Feb;38(2):149-54
pubmed: 24314590
Hemoglobin. 2014;38(5):365-8
pubmed: 25074643
Leuk Res. 2017 Nov;62:108-115
pubmed: 29054020
Eur J Haematol. 2018 Sep;101(3):272-282
pubmed: 29904950
Br J Haematol. 2015 Mar;168(6):882-90
pubmed: 25402221
Blood. 2006 May 1;107(9):3455-62
pubmed: 16352812
Haematologica. 2020 Mar;105(3):640-651
pubmed: 31278207
Expert Rev Hematol. 2016;9(2):151-68
pubmed: 26613264
Biochim Biophys Acta. 2012 Mar;1820(3):403-10
pubmed: 21855608
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
Leukemia. 2015 Jan;29(1):188-95
pubmed: 24854990
Hematology. 2018 Oct;23(9):676-682
pubmed: 29663858
Haematologica. 2016 Jan;101(1):38-45
pubmed: 26385212
Clin Pharmacokinet. 2014 Aug;53(8):679-94
pubmed: 24996374
Blood. 2021 May 27;137(21):3003
pubmed: 34042976
Am J Hematol. 2008 Nov;83(11):858-61
pubmed: 18767130
Haematologica. 2010 Apr;95(4):557-66
pubmed: 19951979
Br J Haematol. 2017 Oct;179(1):83-97
pubmed: 28677895
Clin Nephrol. 2017 Jun;87(6):316-319
pubmed: 27900940
Front Oncol. 2019 Nov 07;9:1186
pubmed: 31788449
Br J Haematol. 2014 Dec;167(5):720-3
pubmed: 25048454
Leukemia. 2018 May;32(5):1254-1258
pubmed: 29568091
Hemasphere. 2017 Dec 20;1(1):e1
pubmed: 31723730
Haematologica. 2013 Jul;98(7):1045-8
pubmed: 23585526
Ann Hematol. 2019 Feb;98(2):339-350
pubmed: 30413901
World J Surg Oncol. 2016 Mar 10;14:77
pubmed: 26965928
Oncol Lett. 2013 Dec;6(6):1774-1778
pubmed: 24260074
Cancer Control. 2012 Oct;19(4 Suppl):4-15
pubmed: 23042420
Front Immunol. 2021 Feb 19;11:627662
pubmed: 33679722
Leuk Res. 2010 Dec;34(12):1576-88
pubmed: 20149927
Clin Exp Med. 2016 Aug;16(3):333-43
pubmed: 25982567
Exp Hematol. 2017 May;49:56-67.e5
pubmed: 28167288
Kidney Int. 2007 Mar;71(6):589-93
pubmed: 17164832
Hematol Oncol. 2018 Feb;36(1):285-290
pubmed: 28512865
Leuk Res. 2010 Sep;34(9):1143-50
pubmed: 20451251
Blood. 2017 Oct 26;130(17):1923-1933
pubmed: 28864815
Eur J Haematol. 2012 Mar;88(3):260-8
pubmed: 22023452
Br J Haematol. 2019 May;185(3):523-531
pubmed: 30828802
Eur J Haematol. 2014 Jun;92(6):527-36
pubmed: 24580147
J Clin Pharm Ther. 2013 Dec;38(6):526-7
pubmed: 23981248
Ann Hematol. 2012 Sep;91(9):1345-9
pubmed: 22569854
Blood Rev. 2018 Sep;32(5):368-377
pubmed: 29602612
Front Oncol. 2021 Mar 22;11:646946
pubmed: 33828991
Am J Blood Res. 2014 Sep 05;4(1):1-6
pubmed: 25232499
Hematology. 2018 Jun;23(5):291-298
pubmed: 29046127
Eur J Haematol. 2017 Mar;98(3):280-288
pubmed: 27859648
Leukemia. 2021 Aug;35(8):2182-2198
pubmed: 34045662
Br J Haematol. 2016 Feb;172(4):512-23
pubmed: 26491866
Ann Hematol. 2015 May;94(5):779-87
pubmed: 25516455
J Clin Oncol. 2010 Jun 10;28(17):2847-52
pubmed: 20421543
Blood. 2010 Oct 7;116(14):2448-54
pubmed: 20566896
QJM. 2014 Apr;107(4):261-9
pubmed: 24368854
Ann Hematol. 2021 May;100(5):1139-1147
pubmed: 33742225
PLoS One. 2017 May 18;12(5):e0175523
pubmed: 28545085
Am J Hematol. 2019 Sep;94(9):E237-E239
pubmed: 31172568
Leuk Res. 2010 Jul;34(7):864-70
pubmed: 20129667
Ann Hematol. 2013 Jan;92(2):191-8
pubmed: 23073603
Haematologica. 2006 Dec;91(12):1588-90
pubmed: 17145593
Oncotarget. 2017 May 30;8(22):36517-36530
pubmed: 28388554
Nat Med. 2016 Mar;22(3):288-97
pubmed: 26878232
Leuk Res. 2019 Jan;76:65-69
pubmed: 30578958
Haematologica. 2019 Feb;104(2):e51-e53
pubmed: 30213831
Eur J Haematol. 2015 Jul;95(1):52-6
pubmed: 25764148
Int J Hematol. 2008 Jul;88(1):16-23
pubmed: 18604581
Br J Haematol. 2021 Sep;194(6):954-969
pubmed: 33855695
Front Oncol. 2019 Apr 26;9:321
pubmed: 31106152
Leuk Lymphoma. 2017 Nov;58(11):2752-2754
pubmed: 28482720
Blood. 2014 Aug 7;124(6):873-81
pubmed: 24923296
Hemasphere. 2019 Oct 30;3(6):e314
pubmed: 31976486
J Nephrol. 2013 Sep-Oct;26(5):821-8
pubmed: 23475461
Blood Rev. 2010 Nov;24(6):239-44
pubmed: 20850917
Br J Haematol. 2017 Jun;177(5):741-750
pubmed: 28419408
Blood. 2006 Oct 15;108(8):2509-19
pubmed: 16778145
Pathophysiology. 2019 Jun;26(2):175-180
pubmed: 30910397
Blood Rev. 2018 Nov;32(6):473-479
pubmed: 29699840
J Clin Oncol. 2012 Jun 10;30(17):2134-9
pubmed: 22547607
Blood Rev. 2018 Jan;32(1):29-35
pubmed: 28847531
Hematol Oncol Clin North Am. 2020 Apr;34(2):465-473
pubmed: 32089223
Pharmacogenomics J. 2015 Jun;15(3):263-71
pubmed: 25348619
Zhonghua Xue Ye Xue Za Zhi. 2013 Oct;34(10):877-82
pubmed: 24171963
Br J Haematol. 2008 May;141(5):728-33
pubmed: 18318756
Am J Hematol. 2013 Apr;88(4):312-6
pubmed: 23450619
Mediterr J Hematol Infect Dis. 2017 Mar 01;9(1):e2017021
pubmed: 28293409
PLoS One. 2013 May 30;8(5):e64114
pubmed: 23737969
Br J Haematol. 2015 Jan;168(2):284-90
pubmed: 25212456
Int J Clin Pharmacol Ther. 2008 Oct;46(10):519-26
pubmed: 18826866
Hematology. 2019 Dec;24(1):426-438
pubmed: 30947625
Leuk Res. 2019 Jan;76:53-57
pubmed: 30572266